##{"id":89306,"date":"2020-10-13T14:33:42","date_gmt":"2020-10-13T03:33:42","guid":{"rendered":"https:\/\/www.fnarena.com\/?p=89306"},"modified":"2020-10-13T14:33:42","modified_gmt":"2020-10-13T03:33:42","slug":"canopy-growth-founder-joins-creso-pharma-as-it-clocks-2m-in-purchase-orders-ytd","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2020\/10\/13\/canopy-growth-founder-joins-creso-pharma-as-it-clocks-2m-in-purchase-orders-ytd\/","title":{"rendered":"Canopy Growth Founder Joins Creso Pharma As It Clocks $2M In Purchase Orders YTD"},"content":{"rendered":"<p style=\"text-align:center\"><em>&#8211;The below is a company-sponsored announcement&#8211;<\/em><\/p>\n<hr \/>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.fnarena.com\/ckfinder\/userfiles\/images\/V2.jpeg\" style=\"height:555px;width:832px\" \/><\/p>\n<p><strong>Though it has had its issues over the past 12 months following the failed A$122M acquisition by TSX listed cannabis company PhamaCielo, Creso Pharma ((CPH)) may be turning the corner.<\/strong><\/p>\n<p>After completing a A$8.992M funding round priced at $0.0291 per share, CPH is largely debt free and appears to be generating more consistent revenue via its Canadian cannabis cultivation facility &ndash; Mernova Medical Inc.<\/p>\n<p>The company has also substantially trimmed its operating costs and brought on high-profile medical cannabis expert, Bruce Linton as a strategic advisor.<\/p>\n<p>Linton was Canopy Growth Corporation&rsquo;s (NYSE: CGC) founder and CEO and took Canopy from market minnow to a peak market capitalisation of approximately US$15 billion.<\/p>\n<p>As chairman and chief executive Linton secured market support for 16 rounds of financing, totalling more than US$5 billion in capital raises and oversaw upwards of US$3 Billion in 30 merger and acquisition transactions.<\/p>\n<p>He has extensive sector experience and holds multiple positions with international companies.<\/p>\n<p>Linton has also worked with large financial institutions including the World Bank and the depth of industry experience he brings to the company will be invaluable at a time when CPH is on the verge of rapid growth.<\/p>\n<p>Discussing the appointment of Linton and the company&rsquo;s broader growth outlook, Creso Director Miri Halperin Wernli said, &ldquo;Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near-term operational milestones and longer-term goals.<\/p>\n<p>&ldquo;We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value.&rdquo;<\/p>\n<p>Linton would be pleased with Creso&rsquo;s progress of late, including its ability to multiply purchase orders.<\/p>\n<p>Creso&rsquo;s repeat purchase orders now total more than $2 million on a year-to-date basis and just this week, the company once again strengthened its revenue profile with another repeat purchase order from South African-based Pharma Dynamics.<\/p>\n<p>This is the second purchase order from Pharma Dynamics for CPH&rsquo;s cannaQIX&reg; product &ndash; sold under the &lsquo;Cannamics&rsquo; brand and follows the successful product launch into the South African market in March 2020.<\/p>\n<p>Pharma Dynamics will distribute Creso Pharma&rsquo;s hemp-based products across South Africa, with plans to extend the distribution to Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.<\/p>\n<p>Non-Executive Chairman Mr Adam Blumenthal said of the deal, &ldquo;Securing this latest purchase order with Pharma Dynamics is a significant development and highlights the multiple opportunities we are witnessing in the region. Creso Pharma is beginning to see a trend in repeat orders from its clients globally which reinforces Creso&rsquo;s high-quality products.&rdquo;<\/p>\n<p>Pharma Dynamics, a subsidiary of the $472.3BN capped Lupin Limited (NSE: LUPIN), currently ranks as the third fastest-growing pharmaceutical company in South Africa, and leads the country in their supply of high-quality generics set at affordable prices.<\/p>\n<p>Pharma Dynamics is well known for investments into innovative wellness programs towards holistic healthcare, with a growing range of over-the-counter products including cold and flu, allergy and immune booster products. Their products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.<\/p>\n<p>This successful partnership is yet another win for Creso Pharma, which as stated has received over $2M in purchase orders year-to-date.&nbsp;<\/p>\n<p>Central to this growth has been their 100% ownership of Mernova Medical Inc. located in Nova Scotia, Canada &ndash; owner of a 24,000 square foot world-class, cannabis growing, revenue-generating, Cultivation and Production Facility.<\/p>\n<p>Mernova, is key to Creso Pharma&rsquo;s market expansion, with <a href=\"https:\/\/finfeed.com\/small-caps\/biotech\/creso-pharma-receive-892m-funding-attracts-canopy-growth-cannabis-pioneer\/\">part of the funds from their $8.92 million backing<\/a> from institutional, professional and sophisticated investors having been earmarked for such initiatives.<\/p>\n<p><a href=\"https:\/\/finfeed.com\/small-caps\/biotech\/creso-pharmas-mernova-receives-initial-purchase-order\/\">Mernova Medicinal received its initial purchase order from Nova Scotia Liquor Corporation (NSLC)<\/a> for the purchase of two of the group&rsquo;s premium strains, HPG 13 and Lemon Haze.<\/p>\n<p>The initial purchase order from Nova Scotia&rsquo;s sole distributor of recreational cannabis had a value of C$180,000 (A$189,000), and the second purchase order had a value of circa $253,000. These orders from Nova Scotia display broad significance as they signalled the group&rsquo;s entry into Canada&rsquo;s retail markets, further diversifying Mernova&rsquo;s revenue streams and adding to their growing wholesale product sales pipeline.<\/p>\n<p>CPH&rsquo;s growing revenue profile and international growth initiatives are further emphasised by Blumenthal: &ldquo;The demand for our product on a global scale vindicates the market share initiatives we have put in place, and the recent sales in Africa and Canada shows that this strategy is not only growing the Company&rsquo;s footprint but also generating significant revenue. We look forward to further capitalising on these opportunities in the near-term.&rdquo;<\/p>\n<hr \/>\n<p><em>Earlier today the corporate announcement above was publicly released. FNArena is acting as a partner in&nbsp;distribution to broaden the reach. No journalists have been involved in the re-publication of this announcement.<\/em><\/p>\n<p><strong>Technical limitations<\/strong><\/p>\n<p><strong><em>If you are reading this story through a third party distribution channel and you cannot see the illustration included<\/em>, <em>we apologise, but technical limitations are to blame.<\/em><\/strong><\/p>\n<p><em>Find out why FNArena subscribers like the service so much: &quot;<a href=\"http:\/\/www.fnarena.com\/index4.cfm?type=dsp_newsitem&amp;n=29EB960D-9DFF-C00E-7F6B464E5D52E250\">Your Feedback (Thank You)<\/a>&quot; &#8211; Warning this story contains unashamedly positive feedback on the service provided.<\/em><\/p>\n<p><em>FNArena&nbsp;is proud about its track record and past achievements: <a href=\"https:\/\/www.fnarena.com\/index.php\/2018\/10\/03\/rudis-view-ten-years-on-the-world-is-still-turning\/\">Ten Years On<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SPONSORED: Though it has had its issues over the past 12 months following the failed A$122M acquisition by TSX listed cannabis company PhamaCielo, Creso Pharma may be turning the corner<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/89306"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=89306"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/89306\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=89306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=89306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=89306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}